Latest news with #DavidLlewellyn
Wales Online
4 days ago
- Wales Online
Man, 39, cupped teenage women's bottoms and whispered sexual comments in their ears
Man, 39, cupped teenage women's bottoms and whispered sexual comments in their ears After assaulting one of his victims, paedophile David Llewellyn said: "Come on, you love it." David Llewellyn, 39, sexually assaulted two teenage women by touching them on their bottoms. (Image: South Wales Police ) A man who had previously been found with indecent images of children sexually assaulted two teenage women by touching them on their bottoms. One of the victims said she had suffered sleepless nights as a result of the assault and was scared to go out at night. Paedophile David Llewellyn, 39, made sexualised comments towards his victims before he assaulted them and would whisper in their ears. This made the victims feel uncomfortable and anxious of being in the defendant's presence. A sentencing hearing at Cardiff Crown Court on Tuesday heard one of the victim's told Llewellyn she was just 19-years-old, to which he responded: "I've done much younger than that." For the latest court reports sign up to our crime newsletter. The first victim described how the defendant got "right in her face" and cornered her when she attempted to back away from him. Llewellyn later "cupped" the victim's bottom and smirked as he told her "Come on, you love it". The second victim said the defendant also touched her bottom. Article continues below When she turned round and accused him of sexually assaulting her, he replied: "Yes, I know." The court heard the victim felt "uncomfortable and vulnerable" following the assault. Llewellyn, of Tyndall Street, Butetown, Cardiff, denied two counts of sexual assault but was found guilty of both charges following a trial. The defendant has four previous convictions, including an offence of making indecent images in 2018. As a result of this conviction, Llewellyn was made subject to a Sexual Harm Prevention Order, which he has breached on a number of occasions. In a victim personal statement read to the court by prosecutor Thomas Stanway, one of the victims said suffered from "sleepless nights" and was "scared to go out at night". In mitigation, Paul Hewitt said his client's situation is "bleak" and "all he has going for him" is his supported accommodation, which he would lose if sent to prison. The defence barrister said the defendant suffers with anxiety, for which he has been prescribed medication. Sentencing, Judge Carl Harrison said the offences were too serious to be dealt with by anything other than an immediate custodial sentence. Article continues below He also said the defendant had "minimised" his actions when he was interviewed by the probation service. Llewellyn was sentenced to six months imprisonment.
Globe and Mail
20-05-2025
- Business
- Globe and Mail
Trailhead Biosystems Announces David Llewellyn, PhD, MBA, as Chief Executive Officer
BEACHWOOD, Ohio , May 20, 2025 /CNW/ -- Trailhead Biosystems Inc. ( a biotechnology company pioneering the creation of iPSC-derived human cells at scale for drug discovery and cell therapy, is pleased to announce the appointment of David Llewellyn, PhD, MBA as its new Chief Executive Officer, and as a member of its Board of Directors. Dr. Llewellyn succeeds Jan Jensen , PhD, who has led the company as Chief Executive Officer and Chief Scientific Officer since its founding. Dr. Jensen will continue with Trailhead Biosystems as Chief Scientific Officer and Board member. "We are pleased to welcome Dr. Llewellyn to the company," said Michael Kaufman , Chairman of the Board of Trailhead Biosystems. "David brings with him over 20 years of experience commercializing life science products. His strong scientific and business acumen will be invaluable as Trailhead continues to innovate and expand." Dr. Jensen reflected on the transition, stating, "Trailhead Biosystems has reached an exciting inflection point, and bringing David Llewellyn on to the executive team marks the start of an ambitious new chapter. His expertise in life sciences and business strategy makes him the right leader to propel us onward, and I look forward to working alongside him to accelerate the commercialization of our groundbreaking technologies." Dr. Llewellyn began his career at MethylGene Inc. as a Medicinal Chemist where he developed a wide range of novel DNA methyltransferase inhibitors to treat cancer. He later joined Aquinox Pharmaceuticals, where he was involved in a variety of different activities including business development, financing and operations. Most recently, Dr. Llewellyn worked with STEMCELL Technologies Inc., where he held several top executive roles including Senior Vice President of Business Operations, Chief Commercial Officer, and Chief Strategy Officer. David holds a BSc in Chemistry from the University of Northern British Columbia , a PhD in Organic Chemistry from McGill University , and an MBA in Strategic Management from the University of British Columbia. "I am honored to step into the role of CEO and join the Board of Trailhead Biosystems," said Dr. Llewellyn. "Trailhead's proprietary High-Dimensional Design-of-Experiments Technology (HD-DoE ®) is a groundbreaking approach for making differentiated induced pluripotent stem cells, and there is no question that it's going to play an important role advancing stem cell research." Trailhead Biosystems is dedicated to revolutionizing medical research and the field of regenerative medicine by developing specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. Under Dr. Llewellyn's leadership, Trailhead plans to expand on its mission of advancing healthcare through scientific innovation with a strong commitment to commercial and scientific excellence.
Yahoo
20-05-2025
- Business
- Yahoo
Trailhead Biosystems Announces David Llewellyn, PhD, MBA, as Chief Executive Officer
BEACHWOOD, Ohio, May 20, 2025 /CNW/ -- Trailhead Biosystems Inc. ( a biotechnology company pioneering the creation of iPSC-derived human cells at scale for drug discovery and cell therapy, is pleased to announce the appointment of David Llewellyn, PhD, MBA as its new Chief Executive Officer, and as a member of its Board of Directors. Dr. Llewellyn succeeds Jan Jensen, PhD, who has led the company as Chief Executive Officer and Chief Scientific Officer since its founding. Dr. Jensen will continue with Trailhead Biosystems as Chief Scientific Officer and Board member. "We are pleased to welcome Dr. Llewellyn to the company," said Michael Kaufman, Chairman of the Board of Trailhead Biosystems. "David brings with him over 20 years of experience commercializing life science products. His strong scientific and business acumen will be invaluable as Trailhead continues to innovate and expand." Dr. Jensen reflected on the transition, stating, "Trailhead Biosystems has reached an exciting inflection point, and bringing David Llewellyn on to the executive team marks the start of an ambitious new chapter. His expertise in life sciences and business strategy makes him the right leader to propel us onward, and I look forward to working alongside him to accelerate the commercialization of our groundbreaking technologies." Dr. Llewellyn began his career at MethylGene Inc. as a Medicinal Chemist where he developed a wide range of novel DNA methyltransferase inhibitors to treat cancer. He later joined Aquinox Pharmaceuticals, where he was involved in a variety of different activities including business development, financing and operations. Most recently, Dr. Llewellyn worked with STEMCELL Technologies Inc., where he held several top executive roles including Senior Vice President of Business Operations, Chief Commercial Officer, and Chief Strategy Officer. David holds a BSc in Chemistry from the University of Northern British Columbia, a PhD in Organic Chemistry from McGill University, and an MBA in Strategic Management from the University of British Columbia. "I am honored to step into the role of CEO and join the Board of Trailhead Biosystems," said Dr. Llewellyn. "Trailhead's proprietary High-Dimensional Design-of-Experiments Technology (HD-DoE®) is a groundbreaking approach for making differentiated induced pluripotent stem cells, and there is no question that it's going to play an important role advancing stem cell research." Trailhead Biosystems is dedicated to revolutionizing medical research and the field of regenerative medicine by developing specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. Under Dr. Llewellyn's leadership, Trailhead plans to expand on its mission of advancing healthcare through scientific innovation with a strong commitment to commercial and scientific excellence. For more information, please contact:Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia:
Cision Canada
20-05-2025
- Business
- Cision Canada
Trailhead Biosystems Announces David Llewellyn, PhD, MBA, as Chief Executive Officer
BEACHWOOD, Ohio, May 20, 2025 /CNW/ -- Trailhead Biosystems Inc. ( a biotechnology company pioneering the creation of iPSC-derived human cells at scale for drug discovery and cell therapy, is pleased to announce the appointment of David Llewellyn, PhD, MBA as its new Chief Executive Officer, and as a member of its Board of Directors. Dr. Llewellyn succeeds Jan Jensen, PhD, who has led the company as Chief Executive Officer and Chief Scientific Officer since its founding. Dr. Jensen will continue with Trailhead Biosystems as Chief Scientific Officer and Board member. "We are pleased to welcome Dr. Llewellyn to the company," said Michael Kaufman, Chairman of the Board of Trailhead Biosystems. "David brings with him over 20 years of experience commercializing life science products. His strong scientific and business acumen will be invaluable as Trailhead continues to innovate and expand." Dr. Jensen reflected on the transition, stating, "Trailhead Biosystems has reached an exciting inflection point, and bringing David Llewellyn on to the executive team marks the start of an ambitious new chapter. His expertise in life sciences and business strategy makes him the right leader to propel us onward, and I look forward to working alongside him to accelerate the commercialization of our groundbreaking technologies." Dr. Llewellyn began his career at MethylGene Inc. as a Medicinal Chemist where he developed a wide range of novel DNA methyltransferase inhibitors to treat cancer. He later joined Aquinox Pharmaceuticals, where he was involved in a variety of different activities including business development, financing and operations. Most recently, Dr. Llewellyn worked with STEMCELL Technologies Inc., where he held several top executive roles including Senior Vice President of Business Operations, Chief Commercial Officer, and Chief Strategy Officer. David holds a BSc in Chemistry from the University of Northern British Columbia, a PhD in Organic Chemistry from McGill University, and an MBA in Strategic Management from the University of British Columbia. "I am honored to step into the role of CEO and join the Board of Trailhead Biosystems," said Dr. Llewellyn. "Trailhead's proprietary High-Dimensional Design-of-Experiments Technology (HD-DoE ®) is a groundbreaking approach for making differentiated induced pluripotent stem cells, and there is no question that it's going to play an important role advancing stem cell research." Trailhead Biosystems is dedicated to revolutionizing medical research and the field of regenerative medicine by developing specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. Under Dr. Llewellyn's leadership, Trailhead plans to expand on its mission of advancing healthcare through scientific innovation with a strong commitment to commercial and scientific excellence.
Yahoo
26-04-2025
- Health
- Yahoo
Massive Study Links 15 Factors to Early Dementia Risk
While dementia is much more common in older adults, hundreds of thousands of people are diagnosed with young-onset dementia (YOD) each year, and an extensive study published in 2023 sheds some considerable light on why. Most previous research in this area has looked at genetics passed down through generations, but here, the team was able to identify 15 different lifestyle and health factors that are associated with YOD risk. "This is the largest and most robust study of its kind ever conducted," said epidemiologist David Llewellyn from the University of Exeter in the UK, when the results were published in December 2023. "Excitingly, for the first time it reveals that we may be able to take action to reduce risk of this debilitating condition, through targeting a range of different factors." The research team analyzed data collected on 356,052 people aged under 65 in the UK. Low socioeconomic status, social isolation, hearing impairment, stroke, diabetes, heart disease, and depression were all associated with a higher risk of YOD. Vitamin D deficiency and high levels of the C-reactive protein (produced by the liver in response to inflammation) also meant a higher risk, as did having two of the ApoE4 ε4 gene variants (a genetic scenario already linked to Alzheimer's disease). The researchers described the relationship between alcohol and YOD as "complex". While alcohol abuse led to an increased risk, moderate to heavy drinking correlated with a reduced risk – possibly because people in this second group are usually healthier in general (bear in mind that those who abstain from alcohol often do so on medical grounds). Higher levels of formal education and lower physical frailty (measured through higher handgrip strength) were also associated with a lower YOD risk. This all helps to fill in some of the knowledge gaps around YOD. "We already knew from research on people who develop dementia at older age that there are a series of modifiable risk factors," said neuroepidemiologist Sebastian Köhler from Maastricht University in the Netherlands. "In addition to physical factors, mental health also plays an important role, including avoiding chronic stress, loneliness, and depression." While the results don't prove dementia is caused by these factors, they help build a more detailed picture. As always in this kind of research, knowing more about the causes can help develop better treatments and preventative measures. Many of these factors are modifiable, which offers more hope for those working to find ways to beat dementia rather than just manage it. Ultimately, dementia may be something we can reduce the risk of by living healthier lives. "Young-onset dementia has a very serious impact, because the people affected usually still have a job, children, and a busy life," said neuroscientist Stevie Hendriks, from Maastricht University. "The cause is often assumed to be genetic, but for many people we don't actually know exactly what the cause is. This is why we also wanted to investigate other risk factors in this study." The research has been published in JAMA Neurology. A version of this article was first published in January 2024. Mattresses Could Be Exposing Kids to Dangerous Chemicals While They Sleep Just 15 Extra Minutes of Sleep Is Linked to Brain Benefits in Young People Study Reveals The Optimal Number of Daily Steps to Offset Sitting Down
